A total of 333 patients were diagnosed with melanoma, non-small cell lung carcinoma (NSCLC), or renal cell carcinoma (RCC) and treated with anti-PD-1, anti-PD-L1, or anti-CTLA-4 therapy. The gene discussed is CTLA4; the disease is hereditary clear cell renal cell carcinoma.